Avenue Therapeutics (NASDAQ:ATXI) Stock Price Down 6.4%

Shares of Avenue Therapeutics, Inc. (NASDAQ:ATXIGet Free Report) traded down 6.4% during trading on Tuesday . The company traded as low as $0.73 and last traded at $0.74. 54,343 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 473,325 shares. The stock had previously closed at $0.79.

Avenue Therapeutics Stock Up 1.4 %

The business has a fifty day moving average of $1.03 and a 200-day moving average of $1.08.

Avenue Therapeutics (NASDAQ:ATXIGet Free Report) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.52) EPS for the quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ATXI. Renaissance Technologies LLC purchased a new stake in Avenue Therapeutics during the 2nd quarter valued at about $34,000. Virtu Financial LLC acquired a new stake in shares of Avenue Therapeutics during the first quarter worth about $28,000. Geode Capital Management LLC boosted its position in Avenue Therapeutics by 359.9% in the second quarter. Geode Capital Management LLC now owns 52,571 shares of the company’s stock valued at $60,000 after buying an additional 41,141 shares during the last quarter. Citadel Advisors LLC acquired a new position in Avenue Therapeutics in the 3rd quarter worth approximately $362,000. Finally, State Street Corp acquired a new position in Avenue Therapeutics in the 1st quarter worth approximately $36,000. Institutional investors and hedge funds own 9.38% of the company’s stock.

About Avenue Therapeutics

(Get Free Report)

Avenue Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.

See Also

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.